Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
A shareholder of OCUL filed a notice of proposed sale under Rule 144 for 3,052 shares of common stock, with an aggregate market value of $27,903.83. The shares were acquired on 01/30/2026 through restricted stock vesting under a registered plan.
The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 02/02/2026. OCUL had 213,047,472 shares of common stock outstanding at the time referenced.
Ocular Therapeutix’s Global Chief Commercial Officer, David Wayne Robinson, reported new equity awards. On January 21, 2026, he received 136,000 restricted stock units (RSUs)$0. Each RSU represents one share of common stock and will vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 416,000 shares of common stock at an exercise price of
Ocular Therapeutix, Inc. officer David Wayne Robinson, who serves as Global Chief Commercial Officer, filed an initial ownership report on Form 3. The filing states that he currently has no securities beneficially owned in Ocular Therapeutix, meaning he reports no direct or indirect holdings of the company’s stock or derivative securities at this time.
Ocular Therapeutix announced that its Chief Financial Officer and Chief Operating Officer, Donald Notman, has taken a temporary medical leave of absence effective January 20, 2026. To ensure continuity in its finance function, the Board appointed Jason Robins, previously Senior Vice President, Finance, as interim Chief Financial Officer, also serving as principal financial and principal accounting officer until Mr. Notman’s anticipated return.
In connection with this interim role, Mr. Robins received a stock option to purchase 33,000 shares of common stock at an exercise price of $11.45 per share, vesting in equal monthly installments over four years under the 2021 Stock Incentive Plan. The company notes there are no related-party transactions or family relationships involving Mr. Robins, and that he entered into its standard indemnification agreement covering certain legal expenses related to his service.
Ocular Therapeutix interim CFO Jason Shand Robins reported receiving a stock option grant linked to common shares of the company. On January 20, 2026, he was awarded a stock option to buy 33,000 shares of Ocular Therapeutix common stock at an exercise price of $11.45 per share. The filing shows he beneficially owns 33,000 derivative securities directly after this grant. The option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on his continued service to the corporation.
Ocular Therapeutix, Inc. filed an initial ownership report for interim CFO Jason Shand Robins, detailing his equity holdings in the company as of January 20, 2026. He directly holds 52,656 shares of common stock, which include 20,917 unvested RSUs from a January 13, 2025 grant and 22,425 unvested RSUs from a January 2, 2026 grant. Each RSU represents one share of common stock and is scheduled to vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal yearly installments.
Robins also holds two stock option awards: one covering 110,600 shares of common stock at an exercise price of $8.12 per share, expiring on January 12, 2035, and another covering 68,195 shares at $11.82 per share, expiring on January 1, 2036. The first option, granted on January 13, 2025, vests over four years with 25% vesting on January 13, 2026 and the balance vesting monthly over the following three years. The second option, granted on January 2, 2026, vests over four years with 1/48 of the underlying shares vesting monthly starting one month after the grant date.
Ocular Therapeutix Chief Legal Officer Todd Anderman reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units (RSUs)$0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share and expiration on January 1, 2036. The option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date. After these transactions, he beneficially owned 152,468 shares of common stock directly.
Ocular Therapeutix Chief Commercial Officer Steve Lawrence Meyers reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and additional one-third portions vesting at the end of each of the next two years, subject to continued service.
He was also granted a stock option covering 197,650 shares of common stock at an exercise price of $11.82 per share. This option vests over four years in equal monthly installments of 1/48 of the shares beginning one month after the grant date, contingent on continued service. Following these transactions, he beneficially owned 217,628 shares of common stock directly.
Ocular Therapeutix reported new equity awards to its Chief Strategy Officer, Sanjay Nayak. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at $0 under the company’s 2021 Stock Incentive Plan.
Subject to his continued service, these RSUs vest over three years in three equal annual installments. He was also granted a stock option for 197,650 shares at an exercise price of $11.82 per share, vesting monthly over four years beginning one month after the grant date, also contingent on continued service. Following the RSU grant, he beneficially owned 342,760 shares of common stock directly.
Ocular Therapeutix, Inc. reported that its Chief Development Officer, Peter Kaiser, received new equity awards on January 2, 2026. He was granted 79,112 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to his continued service.
On the same date, he was also granted a stock option for 240,932 shares of common stock with an exercise price of